Top 10 developments in lupus nephritis

Teresa K. Chen, Derek M. Fine

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

Original languageEnglish (US)
Article number358
JournalCurrent rheumatology reports
Issue number9
StatePublished - Sep 2013


  • APOL1
  • Epidemiology
  • Induction therapy
  • Kidney
  • Lupus nephritis
  • Maintenance therapy
  • Membranous lupus nephritis
  • Multitargeted therapy
  • Mycophenolatemofetil
  • Proliferative lupus nephritis
  • Renal transplantation
  • Rituximab
  • SLE
  • Systemic lupus erythematosus
  • Treatment

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Top 10 developments in lupus nephritis'. Together they form a unique fingerprint.

Cite this